Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Dems' Health Care Reform Plans Would Include Abortion Coverage, Washington Times Opinion Piece States
As lawmakers work to pass health reform legislation, "few are talking about" the "essential question" of whether "health reform will force taxpayers to pay for abortions for the first time in 30 years," Family Research Council President Tony Perkins writes in a Washington Times opinion piece. According to Perkins, "the short answer is yes" because there is no "explicit provision" in any Democratic health plan that would "[p]revent taxpayer funding of abortions as part of the health care benefit Congress is considering"; avert "delays in health care services that result in the death of the patient waiting for care"; or allow health care providers "to refuse to participate in health care-related action that violates their conscience." Perkins continues that the House"s reform proposal would provide federal coverage for ""family planning," the well-worn buzz word that includes abortion unless specified to the contrary." He adds that "it would be naive to assume, unless there is an explicit prohibition in the bill, that [HHS] Secretary Kathleen Sebelius will not use her discretion to fund abortions with taxpayers" money." Perkins also writes that the Democratic reform plans, "in short, ... attempt to be silent on the key question of whether or not to allow the U.S. government to fund abortions with taxpayers" money," and also give the HHS secretary "the power to allow taxpayer-funded abortions."He writes, "The Family Research Council"s answer is clear: There must be a permanent prohibition on taxpayer-funded abortions," as well as "provision to allow a right of conscience for doctors and nurses and other health care providers" to refuse to participate in treatments they oppose. He adds that "there can be no system of denial or delay or rationing of care." Perkins concludes, "Euthanasia by any other name is a poison pill in the health reform debate" (Perkins, Washington Times, 7/5)
generic viagra online
Academy Makes Recommendations To Build Clinical Academic Capacity
UK clinical research is currently benefiting from significant additional investment from Government and other research funders. A challenge for funders and institutions is to allocate res across the range of clinical academic specialties, to most effectively pursue research and its translation into improved healthcare.
plastic surgery before after
News of the day
Greater Likelihood Of Becoming An Adult Smoker If Mother Smoked During Pregnancy And Early Childhood
Children of mothers who smoked during pregnancy and their early childhood years may be predisposed to take up smoking as teens and young adults, compounding the physical damage they sustained from the smoke exposure.
Public Health

Poxel SAS Set Up To Find Innovative Solutions For Metabolic Diseases Management

Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies. Its pipeline consists only of innovative projects with new mechanisms of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies. Poxel has secured several programs from the Merck Serono pipeline. These include a first-in-class project, Imeglimin -which has already achieved its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from the Research until close to clinical development stages. Poxel"s management is composed of a tight and seasoned team of professionals who previously led the Merck Serono diabetes franchise from Research to Clinical & Commercialization. They have a proven track record in the pharmaceutical industry and extensive skills both in project management and technical expertise. The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the complete product life cycle. Poxel"s team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on cardio-metabolic diseases. A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets. All this provides Poxel with a significant competitive advantage. Poxel"s team will be advised by a highly regarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe. Poxel will start the development of its core assets, while seeking funding in order to create additional value from its unique pipeline. Neither Merck KGaA nor Merck Serono is shareholders of Poxel. About Type 2 Diabetes Type 2 Diabetes is defined by a failure of sensitive tissues to respond to insulin, a hormone involved in glucose and fatty acid metabolism, Type 2 diabetes hence being known as non-insulin-dependent diabetes. 90% of diabetic patients in the world suffer from type 2 diabetes. In 2007, more than 220 million people suffered from Type 2 diabetes worldwide, including over 65 million patients in the US and Europe. It is predicted that more than 300 million patients will have this disease by 2025 (IDF). The market is about EUR bn9.6 turnover in 2007, expected to reach EUR bn15 by 2016. Existing therapies on the market are dominated by few dominant product classes, but significant unmet needs remain. Poxel SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009